Craig E Eckfeldt

Assistant Professor of Medicine

Accepting PhD Students

20002023

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

The goal of the research in our lab is to investigate the genetics and signaling pathways that drive acute myeloid leukemia (AML) to provide a foundation for the development of novel targeted treatment approaches. Our research is focused on identifying the critical mediators of RAS signaling that drive AML growth and survival using molecular genetic approaches in the most clinically relevant genetically engineered mouse models, human AML cell lines, and primary AML patient samples in vitro and in patient-derived AML xenografts. We are evaluating the role of clinically-relevant biochemical signaling pathway inhibitors alone and in combination with novel chemotherapeutic and immunotherapy approaches to maximize the translational potential of our studies. We are utilizing cutting-edge multi-parameter flow cytometry and next generation sequencing to characterize AML treatment response and identify potential mechanisms of treatment resistance. In total, these translational studies will provide novel insights for the development of rationally designed targeted therapies for human AML.

Research interests

  • targeted cancer therapy
  • immunotherapy
  • acute myeloid leukemia
  • Ras signaling
  • preclincal models

Fingerprint The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

Research Output

Targeting Ras signaling in AML: RALB is a small GTPase with big potential

Pomeroy, E. J. & Eckfeldt, C. E., Jan 2 2020, In : Small GTPases. 11, 1, p. 39-44 6 p.

Research output: Contribution to journalReview article

  • Dinaciclib enhances natural killer cell cytotoxicity against acute myelogenous leukemia

    Yun, H. D., Schirm, D. K., Felices, M., Miller, J. S. & Eckfeldt, C. E., Aug 27 2019, In : Blood Advances. 3, 16, p. 2448-2452 5 p.

    Research output: Contribution to journalArticle

    Open Access
    1 Scopus citations

    An Indole-Chalcone Inhibits Multidrug-Resistant Cancer Cell Growth by Targeting Microtubules

    Cong, H., Zhao, X., Castle, B. T., Pomeroy, E. J., Zhou, B., Lee, J., Wang, Y., Bian, T., Miao, Z., Zhang, W., Sham, Y. Y., Odde, D. J., Eckfeldt, C. E., Xing, C. & Zhuang, C., Sep 4 2018, In : Molecular pharmaceutics. 15, 9, p. 3892-3900 9 p.

    Research output: Contribution to journalArticle

  • 4 Scopus citations

    A real-world study of clofarabine and cytarabine combination therapy for patients with acute myeloid leukemia

    He, F. C., Sapkota, S., Parker, S. L., De For, T. E., Warlick, E. D., Ustun, C., Eckfeldt, C. E., Rashidi, A., Kurtzweil, A., Weisdorf, D. J. & Bejanyan, N., Oct 3 2018, In : Leukemia and Lymphoma. 59, 10, p. 2352-2359 8 p.

    Research output: Contribution to journalArticle

  • 2 Scopus citations
    Open Access
  • 4 Scopus citations